BioMimetic Therapeutics, Inc. (BMTI) Reports Q3 Loss of $0.25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Join SI Premium – FREE
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) reported Q3 EPS of ($0.25), $0.06 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $428 million versus the consensus estimate of $350 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance
- ConAgra Brands (CAG) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY27 EPS Guidance
- Neogen Corp. (NEOG) Tops Q1 EPS by 3c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
